Related Experiment Video
Updated: Aug 5, 2026
09:06
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
Published on: November 11, 2021
Re-Irradiation in Pediatric Diffuse Midline Glioma: A Multi-Institutional Retrospective Study
Ajay Thomas Alex1, Sean P Hassan1,2,3, Helen Benghiat4
1Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Pediatric Blood & Cancer
|July 29, 2026
Summary
Re-irradiation (RT2) significantly improves survival for children with recurrent diffuse midline gliomas (DMGs). This salvage therapy offers a crucial benefit for patients with limited treatment options after initial radiation (RT1).
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Radiation Oncology
Background:
- Recurrent diffuse midline gliomas (DMGs) in children present limited therapeutic options.
- The efficacy of re-irradiation (RT2) at progression remains uncertain.
Purpose of the Study:
- To evaluate the survival benefit of re-irradiation (RT2) in children with recurrent diffuse midline gliomas (DMGs).
- To identify predictors of overall survival (OS) in this patient population.
Main Methods:
- Retrospective multi-institutional study including 167 children (<18 years) with DMG.
- Patients with radiologic progression after initial radiation (RT1) were analyzed.
- Overall survival (OS) was calculated from progression date; Kaplan-Meier and Cox regression were used.
Main Results:
- 54% of patients received RT2, with a longer interval from RT1 to progression.
- Median OS from progression was significantly longer with RT2 (0.59 years) vs. no RT2 (0.21 years).
- RT2 was the strongest independent predictor of improved survival (HR 0.29, p<0.0001).
Conclusions:
- Re-irradiation (RT2) demonstrates a significant survival benefit for children with recurrent diffuse midline gliomas (DMGs).
- RT2 should be considered a key component of salvage therapy for pediatric DMG patients.
- Further research into optimal RT2 dosing and timing is warranted.
